Andrx
This article was originally published in The Tan Sheet
Executive Summary
Generics firm met with FDA to discuss "inspectional observations" detailed in two Form 483s issued by the agency earlier this year, Andrx announces Sept. 8. The firm detailed corrective measures implemented at its Florida manufacturing facilities, and believes FDA "will be satisfied with the company's corrective action plan, that no regulatory action will be taken" and that the firm will continue to have its ANDAs approved "in due course." CEO Thomas Rice says Andrx is "committed to quality throughout its organization"...You may also be interested in...
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: